Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
:MLYS
RESEARCH TOOLSreports
MLYS Analyst Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MLYS Stock 12 Month Forecast
Average Price Target
$36.86
▲(174.05%Upside)
| Highest Price Target$48.00 | Average Price Target$36.86 | Lowest Price Target$15.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$44
Buy
227.14%
Upside
Reiterated
06/17/25
H.C. Wainwright
$42
Buy
212.27%
Upside
Reiterated
06/17/25
Jefferies
$15
Hold
11.52%
Upside
Initiated
06/11/25
Bank of America Securities
$38
Buy
182.53%
Upside
Reiterated
05/26/25
Guggenheim
$52→$48
Buy
256.88%
Upside
Reiterated
05/13/25
Stifel Nicolaus
$45
Buy
234.57%
Upside
Reiterated
05/13/25
Wells Fargo
$26
Buy
93.31%
Upside
Reiterated
05/12/25
Goldman Sachs
$24
Buy
78.44%
Upside
Reiterated
03/07/25
Goldman Sachs Remains a Buy on Mineralys Therapeutics, Inc. (MLYS)Buy MLYS as we believe that the upcoming pivotal Phase 2 Advance-HTN study results for lorundrostat in uncontrolled and resistant hypertension will set an important impression for subsequent presentations and potentially outperform expectations due to the study’s state-of-the-art design features. 12m target, $24.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$44
Buy
227.14%
Upside
Reiterated
06/17/25
H.C. Wainwright
$42
Buy
212.27%
Upside
Reiterated
06/17/25
Jefferies
$15
Hold
11.52%
Upside
Initiated
06/11/25
Bank of America Securities
$38
Buy
182.53%
Upside
Reiterated
05/26/25
Guggenheim
$52→$48
Buy
256.88%
Upside
Reiterated
05/13/25
Stifel Nicolaus
$45
Buy
234.57%
Upside
Reiterated
05/13/25
Wells Fargo
$26
Buy
93.31%
Upside
Reiterated
05/12/25
Goldman Sachs
$24
Buy
78.44%
Upside
Reiterated
03/07/25
Goldman Sachs Remains a Buy on Mineralys Therapeutics, Inc. (MLYS)Buy MLYS as we believe that the upcoming pivotal Phase 2 Advance-HTN study results for lorundrostat in uncontrolled and resistant hypertension will set an important impression for subsequent presentations and potentially outperform expectations due to the study’s state-of-the-art design features. 12m target, $24.
Best Analysts Covering Mineralys Therapeutics, Inc.
1 Month
xxx
Success Rate
3/8 ratings generated profit
Average Return
+2.21%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 37.50% of your transactions generating a profit, with an average return of +2.21% per trade.
3 Months
xxx
Success Rate
5/8 ratings generated profit
Average Return
+5.58%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +5.58% per trade.
1 Year
Success Rate
9/10 ratings generated profit
Average Return
+17.28%
reiterated a buy rating yesterday
Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +17.28% per trade.
2 Years
xxx
Success Rate
9/10 ratings generated profit
Average Return
+15.63%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +15.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MLYS Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
13
18
18
17
8
Buy
1
1
1
0
0
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
19
19
17
9
Each month's total comprises the sum of three months' worth of ratings.
MLYS Financial Forecast
MLYS Stock Forecast FAQ
What is MLYS’s average 12-month price target, according to analysts?
Based on analyst ratings, Mineralys Therapeutics, Inc.’s 12-month average price target is 36.86.
What is MLYS’s upside potential, based on the analysts’ average price target?
Mineralys Therapeutics, Inc. has 174.05% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MLYS a Buy, Sell or Hold?
Mineralys Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
What is Mineralys Therapeutics, Inc.’s price target?
The average price target for Mineralys Therapeutics, Inc. is 36.86. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $48.00 ,the lowest forecast is $15.00. The average price target represents 174.05% Increase from the current price of $13.45.
The highest analyst price target is $48.00 ,the lowest forecast is $15.00. The average price target represents 174.05% Increase from the current price of $13.45.
What do analysts say about Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of MLYS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.